Two of the more prominent tools for treating femoropopliteal peripheral artery disease — drug-coated balloons and stents — approach the same underlying goal, keeping a treated artery open, in fundamentally different ways. Neither is a universal answer, and the choice between them is shaped by lesion characteristics, vessel location, and clinical judgment rather than a fixed hierarchy. This comparison lays out how each option works and what typically favors one over the other.
The "Leave Nothing Behind" Philosophy of Drug-Coated Balloons
A drug-coated balloon (DCB) is inflated at the treatment site to open the artery mechanically, much like standard angioplasty, but its surface is coated with an anti-restenotic drug, commonly paclitaxel, that transfers to the vessel wall during the brief inflation period. Once the balloon is withdrawn, no permanent implant remains in the artery — hence the "leave nothing behind" framing often used to describe this approach. The rationale is that the drug can inhibit the cellular proliferation responsible for restenosis without the long-term presence of a metal scaffold, which some clinicians view as advantageous in vessels subject to significant mechanical stress, such as the superficial femoral artery.
Why Stents Remain an Important Option
A stent provides mechanical scaffolding that a drug alone cannot replicate. In lesions with significant elastic recoil, calcification, or dissection after angioplasty, a stent may be necessary to keep the artery open regardless of any anti-restenotic coating. Self-expanding nitinol stents, such as INVAMED's Atlas Peripheral Stent System, are engineered to flex with the vessel's natural movement in areas like the femoropopliteal segment, according to manufacturer-reported design features, addressing the mechanical demands that a balloon-only approach cannot.
How Do Clinicians Weigh These Options for Femoropopliteal Disease?
The femoropopliteal segment is a particularly demanding location because it crosses the hip and knee joints and experiences repetitive flexion, extension, and compression with movement, which can affect the durability of any implanted device. Some lesions in this segment are managed well with a drug-coated balloon alone, avoiding an implant in a vessel subject to such mechanical stress, while others — particularly those with significant recoil, dissection, or extensive calcification — may still require stent placement to achieve an adequate result. Lesion length, degree of calcification, and the angiographic result immediately after angioplasty all factor into this decision.
Is One Approach Definitively Better?
Neither drug-coated balloons nor stents are universally superior; each has typical advantages and trade-offs that make it more or less suited to a specific lesion. DCBs avoid a permanent implant but depend on an adequate initial angioplasty result to work well, since they do not provide independent mechanical support. Stents provide durable scaffolding but introduce a permanent metal structure into a mechanically active vessel segment. The appropriate choice depends on the individual patient's anatomy and lesion characteristics, determined by clinical judgment rather than a one-size-fits-all rule.
Where INVAMED's Devices Fit Into This Comparison
INVAMED's Extender Drug (Eluting) PTA Balloon Catheter is a paclitaxel drug-coated balloon designed for peripheral use, available in a range of balloon diameters and lengths with radiopaque markers for placement accuracy, according to manufacturer-reported specifications; the company also cites a study of combined atherectomy and this DCB in lower-extremity lesions reporting 97.0% technical success against an 86% performance goal, as stated by the manufacturer. The Atlas Peripheral Stent System complements this offering for lesions requiring mechanical scaffolding. Full details are available on the peripheral arterial disease product page.
Does a drug-coated balloon eliminate the risk of the artery re-narrowing?
No treatment can guarantee that an artery will not re-narrow over time. Drug-coated balloons are intended to reduce the likelihood of restenosis compared to angioplasty alone, but they do not eliminate the possibility, and follow-up monitoring remains important regardless of the treatment approach used.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.